Oxford Biomedica Share News (OXB)

Oxford Biomedica Information

Buy OXB Shares
Add OXB to Watchlist
Add OXB to Alert

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 327.00

Bid: 328.50

Ask: 330.50

Change: -7.50 (-2.24%)

Spread: 2.00 (0.609%)

Open: 329.00

High: 332.50

Low: 321.00

Prev. Close: 334.50

Last checked at -

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

Tue, 05th Dec 2023 10:02

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

----------

FTSE 100

----------

Exane BNP raises Antofagasta price target to 1,210 (1,190) pence - 'underperform'

----------

Exane BNP raises Rio Tinto to 'outperform' - price target 6,500 pence

----------

Barclays cuts Anglo American price target to 2,865 (2,900) pence - 'overweight'

----------

Goldman Sachs raises Segro price target to 680 (580) pence - 'sell'

----------

Goldman Sachs raises Land Securities to 'buy' (neutral) - price target 690 (580) pence

----------

JPMorgan cuts Hikma price target to 2,200 (2,350) pence - 'overweight'

----------

JPMorgan raises GSK price target to 1,450 (1,400) pence - 'underweight'

----------

JPMorgan cuts AstraZeneca price target to 13,000 (14,000) pence - 'overweight'

----------

Jefferies cuts Compass price target to 2,410 (2,575) pence - 'buy'

----------

Jefferies cuts Entain price target to 890 (915) pence - 'hold'

----------

FTSE 250

----------

Goldman Sachs raises Big Yellow price target to 1,350 (1,280) pence - 'buy'

----------

Goldman Sachs raises Tritax Big Box price target to 180 (160) pence - 'buy'

----------

Goldman Sachs raises Great Portland price target to 380 (360) pence - 'neutral'

----------

Goldman Sachs raises Derwent London price target to 2,319 (2,076) pence - 'buy'

----------

Goldman Sachs raises Supermarket Income REIT price target to 90 (85) pence - 'buy'

----------

Goldman Sachs raises Hammerson price target to 15 (12) pence - 'sell'

----------

Goldman Sachs raises British Land to 'neutral' (sell) - price target 350 (290) pence

----------

RBC cuts Dr Martens price target to 100 (150) pence - 'sector perform'

----------

Barclays cuts Auction Technology to 'equal weight' (overweight) - price target 600 (880) pence

----------

SMALL CAP, AIM and OTHER MAIN MARKET

----------

Goldman Sachs cuts ITM Power price target to 52 (57) pence - 'sell'

----------

JPMorgan cuts Oxford Nanopore price target to 325 (390) pence - 'overweight'

----------

JPMorgan cuts Oxford BioMedica price target to 210 (325) pence - 'neutral'

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

More News

10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Latest Share Chat

Oxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

Login to your account

Quickpicks are a member only feature

Login to your account